Cardioprotective effect of rosmarinic acid against myocardial ischaemia/reperfusion injury via suppression of the NF-κB inflammatory signalling pathway and ROS production in mice

Wei Quan,Hui-xian Liu,Wei Zhang,Wei-juan Lou,Yang-ze Gong,Chong Yuan,Qing Shao,Na Wang,Chao Guo,Fei Liu
DOI: https://doi.org/10.1080/13880209.2021.1878236
2021-01-01
Pharmaceutical Biology
Abstract:<span>Rosmarinic acid (RosA), a natural poly-phenolic compound isolated from a variety of Labiatae herbs, has been reported to have a range of biological effects. To investigate the cardioprotective effects of RosA against myocardial ischaemia/reperfusion (I/R) injury.Male C57BL/6J mice were given RosA (100 mg/kg) via intragastric administration. After 1 week of administration, the mice were subjected to 30 min/24 h myocardial I/R injury. The mice were randomly subdivided into 4 groups: Vehicle, RosA, Vehicle + I/R, and RosA + I/R. Infarct size (IS), cardiac function (including EF, FS), histopathology, serum enzyme activities, ROS changes, cis aconitase (ACO) activity, and specific mRNA and protein levels were assessed <i>in vivo</i>. HL-1 cells were pre-treated with or without RosA (50 μM), followed by stimulation with 9 h/6 h of oxygen and glucose deprivation/re-oxygenation (OGD/R). The cells were randomly subdivided into 4 groups: Vehicle, RosA, Vehicle + OGD/R, and RosA + OGD/R. Lactate dehydrogenase (LDH) levels, ACO activity, ROS changes and protein levels were measured <i>in vitro</i>.Treatment with RosA reduced the following indicators <i>in vivo</i> (<i>p</i> &lt; 0.05): (1) IS (14.5%); (2) EF (-23.4%) and FS (-18.4%); (3) the myocardial injury enzymes CK-MB (20.8 ng/mL) and cTnI (7.7 ng/mL); (4) DHE-ROS: (94.1%); (5) ACO activity (-2.1 mU/mg protein); (6) <i>ogdh</i> mRNA level (122.9%); and (7) OGDH protein level (69.9%). Moreover, treatment with RosA attenuated the following indicators <i>in vitro</i> (<i>p</i> &lt; 0.05): (1) LDH level (191 U/L); (2) DHE-ROS: (165.2%); (3) ACO activity (-3.2 mU/mg protein); (4) <i>ogdh</i> mRNA level (70.0%); and (5) OGDH (110.1%), p-IκB-a (56.8%), and p-NF-κB (57.7%) protein levels.RosA has the potential to treat myocardial I/R injury with potential application in the clinic.</span>
pharmacology & pharmacy,medical laboratory technology,plant sciences
What problem does this paper attempt to address?